Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Azad on the Importance of Germline Testing in CRC

October 19th 2020

Nilofer Saba Azad, MD, discusses the significance of germline testing in colorectal cancer.

IDE196/Crizotinib Combo Under Exploration in GNAQ/11+ Solid Tumors

October 18th 2020

An ongoing, collaborative clinical trial has been expanded to evaluate the investigational protein kinase C inhibitor IDE196 in combination with the multikinase inhibitor crizotinib (Xalkori) for patients with GNAQ- or GNA11-mutated solid tumors, including metastatic uveal melanoma , skin melanoma, lung cancer, and colorectal cancer.

Dr. Azad on Treatment Considerations in Right- Versus Left-Sided CRC

October 16th 2020

Nilofer Saba Azad, MD, discusses treatment considerations in right- versus left-sided colorectal cancer.

Dr. Marshall on Challenges With Sequencing in CRC

October 15th 2020

John L. Marshall, MD, discusses sequencing challenges in colorectal cancer.

Dr. Siena on the Rationale for the DESTINY-CRC01 in Metastatic CRC

October 15th 2020

Salvatore Siena, MD, discusses the rationale for the phase 2 DESTINY-CRC01 trial in metastatic colorectal cancer.

Dr. Azad on Remaining Challenges in CRC

October 15th 2020

Nilofer Saba Azad, MD, discusses remaining challenges in colorectal cancer.

Dr. Kopetz on the Design of the BEACON CRC Trial in BRAF V600E-Mutant mCRC

October 15th 2020

Scott Kopetz, MD, PhD, FACP, discusses the design of the phase 3 BEACON CRC trial in metastatic colorectal cancer.

Dr. Bekaii-Saab on the Emergence of Targeted Therapy in CRC

October 14th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the emergence of targeted therapy in colorectal cancer.

Dr. Chu on the Importance of Identifying MSI Status in mCRC

October 14th 2020

Edward Chu, MD, MMS, discusses the importance of identifying patients with microsatellite instability–high metastatic colorectal cancer.

Dr. Farrington on the Importance of Genetic Testing in CRC

October 13th 2020

Caroline Farrington, PhD, discusses the importance of genetic testing in colorectal cancer.

Onvansertib Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutated mCRC

October 5th 2020

The combination of onvansertib plus with 5-fluorouracil, FOLFIRI, and bevacizumab was shown to have preliminary efficacy with acceptable safety when used as a second-line treatment for patients with KRAS-mutated metastatic colorectal cancer.

Stoffel Underscores Importance of Germline Testing for Lynch Syndrome

October 2nd 2020

Elena M. Stoffel, MD, MPH, discusses the importance of genetic testing in detecting Lynch syndrome and other hereditary syndromes associated with risk of colorectal cancer and other diseases.

Regorafenib/Nivolumab Shows Modest Activity in MMR Proficient Advanced Refractory CRC

October 1st 2020

Richard D. Kim, MD, discusses the potential of regorafenib plus nivolumab in patients with advanced colorectal cancer and the need for biomarkers to predict response to the regimen.

Dr. Chu on the Role of Pembrolizumab in dMMR/MSI-H mCRC

October 1st 2020

Edward Chu, MD, MMS, discusses the role of pembrolizumab in patients with mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer.

Palliative Care for Young Adults Is a Growing Reality in CRC

September 24th 2020

Although most younger patients received diagnoses of cancer of the rectum or distal colon, incidence rates are increasing across all colorectal anatomic subsites.

First-Line Pembrolizumab Improves Health-Related Quality of Life in DNA Repair-Deficient Metastatic Colorectal Cancer

September 19th 2020

As first-line therapy for patients with microsatellite instability-high and/or mismatch-repair deficient metastatic colorectal cancer, pembrolizumab improves quality of life compared with standard chemotherapy.

Preclinical Data Suggest Novel Molecule Enhances Immunotherapy Response in CRC

September 17th 2020

Timothy Cragin Wang, MD, discusses the advent of immunotherapy and how it has revolutionized multiple areas of cancer treatment; however, the transformative potential of the modality has been mild in the field of colorectal cancer.

Dr. Farrington on the Importance of Patient Advocacy in CRC

September 16th 2020

Caroline Farrington, PhD, discusses the importance of patient advocacy in colorectal cancer.

Dr. VanderWalde on the Importance of Multidisciplinary Care in Rectal Cancer

September 15th 2020

Noam VanderWalde, MD, MS, discusses the importance of implementing multidisciplinary care for patients with rectal cancer.

Dr. Grothey on Choosing Between Regorafenib and TAS-102 in mCRC

September 14th 2020

Axel Grothey, MD, discusses factors to consider when selecting between regorafenib and trifluridine/tipiracil in metastatic colorectal cancer.